Redeye returns with a research update following Annexin's Q2 report.
Redeye provides a research update following the Q2 report recently published by Isofol.
Medivir raised SEK140m in a directed share issue in June at an attractive price point funding a new ...
* Financials fairly in line * Entering the final stage of Phase 1b, Phase 2 expected by YE'26 * Fair...
Solwers reported its results for Q2 with sales of EUR 20.
Högre försäljning men fortsatt svagt resultat Nettoomsättningen ökade med 6,3 % till 50,1 MSEK (47,...
On Friday, BVB published preliminary FY25/26 figures, showing a declining top line and profitability...
* As flagged, Q2 was soft on postponed ODM/WL orders * We expect a seasonally stronger H2e * Mgmt.
Redeye comments on a series of order wins and business developments announced by Goodbye Kansas over...
Flowscape levererade lönsam tillväxt med +9 % omsättning och ARR.
Endomines announced today (24 August) that the company is moving its Pampalo processing plant to a 2...
* Sales grew 26% organically, ahead of expectations * Sweden remains a clear profit driver despite m...
* Q2e: 6% revenue growth y-o-y * '26e adj. EBITDA just below the low end of '26 guidance * Trading ~...
* Falling CBD and hemp demand plus regulatory uncertainty triggered portfolio-wide liquidations and ...
* Q2 organic growth of +91% marks a record quarter * We raise '26e-'28e sales by 7% and EBIT by 23%,...
Crunchfish’s Q2 report largely reinforces the investment case outlined in our previous update, with ...
Sustainion redovisade ett mycket starkt andra kvartal med nettoomsättning om 240,0 MSEK (+91,0 %), v...
Angler Gaming levererade ett starkt Q2’26 med en omsättning på 8,45 MEUR (6,64), motsvarande en till...
Redeye comments on CLS’s rights issue outcome and adjusts our model accordingly.
Vi inleder bevakning på SaveLend, ett svenskt fintechbolag som driver en digital sparplattform där p...
